150 results
425
ONCT
Oncternal Therapeutics Inc
3 Jun 19
Business combination disclosure
4:27pm
Group.
“The cirmtuzumab and ibrutinib combination has demonstrated impressive clinical activity in this interim assessment of data from these patients … evaluated in the interim safety assessment of the study, the Cirmtuzumab + Ibrutinib combination was well-tolerated, with adverse events that were typical
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
14 Aug 18
GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results
7:30am
assessment in the first 225 patients enrolled. These data will be announced simultaneously with the ASTRID results. Once the 225-patient cohort completes … the four-month, off-drug durability assessment, those patients will have, at their discretion, the option to enter
an additional five-month, off-drug
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
14 Sep 05
Other Events
12:00am
and Financial Analysis
GTx, Inc.
(901) 523-9700
GTx Receives FDA Response on Special Protocol Assessment for
ACAPODENE … Protocol Assessment (SPA) on the design
of its pivotal Phase III clinical trial of ACAPODENE(R) for the prevention of
prostate cancer in high risk men
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
14 Mar 13
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function In Patients with Cancer Published In the Lancet Oncology
12:00am
at baseline and Day 113/end of study. Efficacy analyses were done in the approximately 100 patients who had both a baseline and an on-treatment assessment … test (power). Durability of enobosarm treatment will be assessed at five months. Secondary endpoints include an assessment of whether enobosarm-treated
8-K
EX-99.1
f08i j96mgdqpya2k3vc
9 Jun 10
Other Events
12:00am
8-K
EX-99.1
2thuzgflqeqhdj2
19 Aug 13
Other Events
12:00am
S-8
EX-23.1
qyt7oypbv46p hx
11 Aug 06
Registration of securities for employees
12:00am
8-K
tmmd6m99vizvltfi7d3
14 Sep 05
Other Events
12:00am
DEFA14A
657ctjdd
15 Apr 14
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
o875on76ytzqf3z0dxw
15 Apr 13
Other Events
12:00am
8-K
EX-99.1
hib7o61fz
24 Apr 06
Other Events
12:00am
10-Q
EX-10.24
wwnn5bqgza
7 May 04
Quarterly report
12:00am
8-K
EX-99.1
wq4scpgc
19 Oct 05
Other Events
12:00am
8-K
EX-99.1
w3m s0zhar1n0s
23 May 08
GTx Announces Phase III PIN Clinical Trial Will Continue As Planned
12:00am
8-K
EX-99.1
iuyco3ih9
22 Jun 06
Other Events
12:00am